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Abstract
Background: It remains unclear whether disease course in multiple sclerosis (MS) is influenced by genetic polymorphisms.
Here, we aimed to identify genetic variants associated with benign and aggressive disease courses in MS patients.
Methods: MS patients were classified into benign and aggressive phenotypes according to clinical criteria. We performed
exome sequencing in a discovery cohort, which included 20 MS patients, 10 with benign and 10 with aggressive disease
course, and genotyping in 2 independent validation cohorts. The first validation cohort encompassed 194 MS patients, 107
with benign and 87 with aggressive phenotypes. The second validation cohort comprised 257 patients, of whom 224
patients had benign phenotypes and 33 aggressive disease courses. Brain immunohistochemistries were performed using
disease course associated genes antibodies.
Results: By means of single-nucleotide polymorphism (SNP) detection and comparison of allele frequencies between
patients with benign and aggressive phenotypes, a total of 16 SNPs were selected for validation from the exome
sequencing data in the discovery cohort. Meta-analysis of genotyping results in two validation cohorts revealed two
polymorphisms, rs28469012 and rs10894768, significantly associated with disease course. SNP rs28469012 is located in
CPXM2 (carboxypeptidase X, M14 family, member 2) and was associated with aggressive disease course (uncorrected
p value < 0.05). SNP rs10894768, which is positioned in IGSF9B (immunoglobulin superfamily member 9B) was associated
with benign phenotype (uncorrected p value < 0.05). In addition, a trend for association with benign phenotype was
observed for a third SNP, rs10423927, in NLRP9 (NLR family pyrin domain containing 9). Brain immunohistochemistries in
chronic active lesions from MS patients revealed expression of IGSF9B in astrocytes and macrophages/microglial cells, and
expression of CPXM2 and NLRP9 restricted to brain macrophages/microglia.
Conclusions: Genetic variants located in CPXM2, IGSF9B, and NLRP9 have the potential to modulate disease course in MS
patients and may be used as disease activity biomarkers to identify patients with divergent disease courses. Altogether,
the reported results from this study support the influence of genetic factors in MS disease course and may help to better
understand the complex molecular mechanisms underlying disease pathogenesis.
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Background
Multiple sclerosis (MS [MIM: 126200]) is a common
disease of the central nervous system (CNS) of complex
pathogenesis. Although the etiology of MS is unknown,
it is assumed that both genetic and environmental fac-
tors, such as cigarette smoking, vitamin D deficiency,
viral infections, or obesity, influence disease phenotype
[1–3]. Additionally, there is increasing evidence that
inherited epigenetic variation complements the role of
the genetic predisposition in the susceptibility to develop
MS [4]. Over the last years, genome-wide association
studies (GWAS) have significantly contributed to the
characterization of the MS genetic component, with the
identification of more than 200 genetic variants outside
the major histocompatibility complex (MHC) that influ-
ence the risk of developing MS [2–5]. Despite the grow-
ing knowledge of MS risk genes, still little is known
about the disease-modifying genes that modulate MS
course. Disease course in MS is extremely variable and
patients may have relapse-onset or progressive clinical
forms, and face benign or severe disease courses.
Although the underlying cause of this disease variability
remains elusive, evidence exists that it may be influenced
by genetic factors [6, 7].
In the present study, we aimed to identify genes as-
sociated with MS disease course by first applying an
exome sequencing approach to a discovery cohort of
MS patients with benign and aggressive disease
courses, followed by the validation of selected genetic
variants in two independent cohorts of patients with
divergent disease courses.
Methods
Discovery cohort
The discovery cohort comprised 20 MS patients classi-
fied according to their disease course into benign and
aggressive phenotypes. Patients with benign phenotypes
(n = 10) were defined as having an Expanded Disability
Status Scale (EDSS) equal or lower than 3.0 after 15 or
more years from disease onset [8] and never received
MS therapies. Patients with aggressive disease courses
(n = 10) reached an EDSS score equal or higher than 6.0
within the first 5 years after disease onset, regardless of
treatment [9]. All patients included in the discovery co-
hort were recruited at the Centre d’Esclerosi Múltiple de
Catalunya (Cemcat). Additional file 1: Table S1 summa-
rizes demographic and main clinical characteristics of
the discovery cohort.
Exome sequencing
Genomic DNA was extracted from peripheral blood
using standard methods. An exome sequencing ap-
proach was applied to the discovery cohort in order to
identify genes associated with benign and aggressive
disease courses. Exome sequencing was based on an
Illumina HiSeq2000 sequencing platform and an
Agilent’s SureSelect Target Enrichment System for 51 Mb.
Sequencing was done with a 50× of coverage and reads
were aligned against the human reference genome
(GRCh37/hg19 assembly) using the Burrows-Wheeler
Alignment tool (BWA) [10]. After reads mapping,
low-quality reads and sequences flagged as PCR duplicates
were removed from the BAM file using the Sequence
Alignment/Map (SAM) [10] and Picard Tools. Unmasked
variants were annotated considering all possible
transcripts for each target gene, and in some cases variants
located within a coding sequence when considering one
isoform could be positioned within a non-coding region
when considering another isoform, thus resulting also in
the identification of intronic variants. Exome sequencing
was performed in Sistemas Genómicos (Valencia, Spain).
Selection of candidate single-nucleotide polymorphisms
for validation
For the variant calling process, different algorithms were
applied, including VarScan [11] and the Genome Analysis
Toolkit (GATK) [12]. Python scripts were developed to
combine variants. Variants annotation was based on
Ensembl and NCBI databases. For the selection of signifi-
cant variants, a Fisher exact test was applied to the benign
and aggressive phenotypes. For prioritization and selection
of the most promising variants, the following criteria were
applied: (i) presence of two or more statistically significant
variants per gene; (ii) odds ratio difference of the prevalence
for the variant between disease phenotypes equal or higher
than 2; (iii) absence of the variant in one disease phenotype
and presence of the variant in ≥ 50% of patients belonging
to the counterpart phenotype; (iv) missense variants, splice
region variants, and variants reported as possible deleteri-
ous mutations; and (v) biological and functional relevance
of the target genes to MS, as reported in the literature. A
total of 16 independent variants satisfying 2 or more of the
aforementioned criteria were selected for validation.
Validation cohorts
Two independent cohorts with benign and aggressive
disease courses were included in the study in order to
validate the selected variants from the exome sequencing
approach.
The first validation cohort included 194 MS patients
from 7 MS centers [Bilbao (n = 56); UCSF (n = 55);
Madrid—Hospital Clínico (n = 32); Barcelona—Hospital
Clinic (n = 23); Madrid—Ramón y Cajal (n = 16);
Madrid—Puerta de Hierro (n = 9); Girona (n = 3)]. Of
these, 107 MS patients had benign phenotypes and 87
aggressive disease courses.
The second validation cohort consisted of 257 MS pa-
tients from Canada, 224 patients with benign phenotypes
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and 33 with aggressive disease courses. MS patients were
ascertained through the Canadian Collaborative Project
on the Genetic Susceptibility to Multiple Sclerosis
(CCPGSMS) [13].
Clinical criteria to classify patients into benign and ag-
gressive disease courses were the same as those applied
to the discovery cohort, except for the second validation
cohort in which treatment information on patients with
benign disease course was not available. Similar to the
discovery cohort, patients with benign phenotypes from
the first validation cohort never received MS therapies.
A summary of demographic and clinical characteristics
of the first and second validation cohorts is shown in
Additional file 1: Table S1.
The study was approved by the corresponding local
ethics committees, and all participants provided in-
formed consent.
TaqMan OpenArray genotyping
Genotyping of selected variants in the first validation
cohort was performed using an OpenArray technology
(Thermo Fisher Scientific, Massachusetts, USA) and fol-
lowing the manufacturer’s instructions. Briefly, DNA
samples were loaded into custom designed arrays using an
OpenArray® AccuFill System (Thermo Fisher Scientific).
QuantStudio™ 12K Flex system (Thermo Fisher Scientific)
was used for sample amplification and fluorescent data
collection. Hapmap samples with known genotype were
included as internal controls of the process. Genotype was
assigned using Taqman Genotyper Software (Thermo
Fisher Scientific). Genotyping was performed by the
Human Genotyping laboratory of the Spanish National
Cancer Research Centre (CNIO).
Sequenom MassARRAY genotyping
In the second validation cohort, selected variants were
genotyped using a MassArray iPLEX platform (Sequenom,
San Diego, CA, USA) as previously described [14].
CPXM2, IGSF9B, and NLRP9 expression analysis in
peripheral blood cells
Gene expression levels for CPMX2, NLRP9, and IGSF9B
were determined by real-time PCR in peripheral blood
mononuclear cells (PBMC) available from a subgroup of
untreated MS patients from the first validation cohort.
In order to avoid a confounding effect of disease course
in the expression levels for these genes, analysis was re-
stricted to the group of patients with aggressive disease
course (n = 8 for CPXM2; n = 9 for NLRP9; n = 7 for
IGSF9B). Briefly, PBMC were isolated by Ficoll-Isopaque
density gradient centrifugation (Gibco BRL, Life Technolo-
gies LTD, Paisley, UK) and stored in liquid nitrogen until
used. Total RNA was extracted from PBMC using TRIzol®
reagent (Invitrogen, Carlsbad, CA) and cDNA synthesized
using the High Capacity cDNA Archive kit (Applied Biosys-
tems, Foster City, CA, USA). Messenger RNA expression
levels for CPMX2, NLRP9, and IGSF9B were determined by
real-time PCR using TaqMan® probes specific for each gene
(Applied Biosystems, Foster City, CA, USA). The house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an endogenous control (Applied
Biosystems). Assays were run on the ABI PRISM® 7900HT
system (Applied Biosystems) and data were analyzed using
the 2−ΔΔCT method [15]. Results were expressed as fold
change in gene expression in MS patients carrying the risk
allele relative to non-carrier patients.
Immunohistochemistry for CPXM2, IGSF9B, and NLRP9 in
MS brain tissue
Paraffin-embedded brain samples of chronic active lesions
from four MS patients were provided by the UK Multiple
Sclerosis Tissue Bank and stained with hematoxylin and
eosin (HE) and Klüver-Barrera (KB) for inflammation and
demyelination assessment. Four-micrometer-thick,
paraffin-embedded serial sections were deparaffined in
xylene and rehydrated in alcohol. Endogenous peroxidase
activity was blocked with hydrogen peroxide (2%), metha-
nol (70%), and PBS for 20 min. Antigen retrieval was per-
formed in TE buffer (1 M TrismaBase and 1 mM EDTA)
(pH = 9) in the microwave. Non-specific protein binding
was blocked with 0.2% of bovine albumin (BSA) in PBS.
Sections were incubated overnight at 4 °C with the follow-
ing primary antibodies: rabbit anti-CPXM2 (Biorbyt),
rabbit anti-NLRP9 (Abcam), and rabbit anti-IGSG9B
(Abcam). Samples were incubated for 1 h at room
temperature with goat-anti rabbit HRP secondary anti-
body (Dakocytomation) and stainings were visualized with
3,3′diaminobenzidine (Sigma, St Louis, MO, USA) as a
chromogenic substrate.
Results
Exome sequencing in the discovery cohort of patients
with benign and aggressive disease courses and selection
of candidate genetic variants
A flowchart summarizing the main steps of the study
design and analysis is depicted in Fig. 1. In order to
identify genetic variants associated with disease
course, we first performed exome sequencing in an
initial cohort of 20 MS patients classified according
to their disease course into benign (n = 10) and ag-
gressive (n = 10). A total of 915 single-nucleotide
polymorphisms (SNPs) were differentially distributed
between MS patients with benign and aggressive
disease courses (uncorrected p values < 0.05; data
not shown). From the list of differentially distributed
SNPs and after applying the selection criteria de-
scribed in the “Methods” section, 16 SNPs were
chosen for validation in two validation cohorts.
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Table 1 shows a description of the 16 selected SNPs
from the discovery cohort, and Table 2 provides the
results of the exome sequencing analysis for these 16
SNPs.
Validation of selected SNPs in two independent cohorts
of patients with benign and aggressive disease courses
Selected SNPs were genotyped in two independent
validation cohorts composed of MS patients classified
according to their disease course. A total of 194 MS pa-
tients were included in the first validation cohort and
257 MS patients in the second validation cohort.
Meta-analysis of genotyping results in both cohorts
identified two SNPs, rs28469012 and rs10894768, signifi-
cantly associated with MS disease course. As shown in
Fig. 2, the minor allele for rs28469012, an intronic SNP
positioned in CPXM2 (carboxypeptidase X, M14 family,
member 2), was nominally significantly associated with
more aggressive disease course [p-value; odds ratio (95%
confidence interval): p = 0.04; 1.81 (1.03–3.18)] (Fig. 2).
In this case, a modest degree of heterogeneity was found
between both validation cohorts.
The minor allele for rs10894768, which corresponds to
a synonymous SNP located in IGSF9B (immunoglobulin
superfamily member 9B), was nominally significantly as-
sociated with benign disease course [p = 0.04; 0.70
(0.49–0.99)]. Meta-analysis of this variant supported the
originally identified association with homogeneous out-
comes for both cohorts (I2 = 0).
A trend for significance was observed in a third SNP,
rs10423927, an intronic variant located in NLRP9 (NLR
family pyrin domain containing 9), with the minor allele
associated with benign disease course [p = 0.09; 0.58
(0.31–1.09)]. Similar to the IGSF9B variant, meta-analysis
for rs10423927 also supported the association in the dis-
covery cohort and resulted in similar outcomes in both
validation cohorts (I2 = 0).
It should be noted that rs2374639, a synonymous
variant positioned in VPS50 (VPS50, EARP/GARPII
complex subunit), showed a significant association in
the second validation cohort with the same protective
effect observed in the discovery cohort [p = 0.04; 0.47
(0.23–0.95)]. However, the heterogeneity found
between both validation cohorts did not allow to per-
form a joint analysis (Table 2; I2 = 80%).
Genotyping frequencies and results of statistical
analysis in the two validation cohorts for all selected
variants are provided in Table 2.
Tissue-specific expression of IGSF9B, CPXM2, and NLRP9
In order to explore the functional consequences of
the polymorphisms associated with MS disease
course, we first investigated whether mRNA expres-
sion levels for IGSF9B, CPXM2, and NLRP9 in
Fig. 1 Flowchart showing the study design and analysis. Patients were classified according to their disease course into benign and aggressive
MS, as described in the Methods. By means of exome sequencing, a total of 915 single-nucleotide polymorphisms (SNPs) were identified from 10
MS patients with benign and 10 with aggressive disease courses as being differentially distributed between both groups (discovery cohort). After
applying several selection criteria on the list of 915 SNPs including odds ratio difference, phenotype prevalence, number of statistically significant
SNPs per gene, type and variant effects on the predicted protein, and relevance of target genes to MS, a total of 16 SNPs were chosen for further
validation in two independent cohorts of patients also classified into benign and aggressive phenotypes. The first validation cohort comprised
194 MS patients, 107 with benign and 87 with aggressive disease courses, and genotyping was conducting using an OpenArray technology. The
second validation cohort consisted of 257 MS patients, 224 with benign and 33 with aggressive disease courses, and genotyping was performed
on a MassArray iPLEX platform. Finally, a meta-analysis was performed in the two validation cohorts
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PBMC differed between MS patients carrying the
minor allele associated with disease course and
non-carrier patients. CPXM2 and NLRP9 expression
was not detected in PBMC from MS patients (data
not shown). IGSF9B expression was detected in
PBMC from MS patients, although no differences
were observed between carriers and non-carriers of
the minor allele associated with benign disease
course (Additional file 1: Figure S1).
In order to determine whether the selected genetic
variants associated with disease course could be
modifying the expression of nearby genes in the re-
gion, we analyzed cis-expression quantitative trait
loci (eQTLs) in 48 tissues from the Genotype-Tissue
Expression (GTEx) project [16], lymphoblastoid cell
lines in 465 individuals from the Geuvadis project
[17], and trans-eQTLs from expression data of 9196
tumor samples in 33 cancer types from the Pan-
canQTL study [18]. We observed correlation of the
rs10894768 genotypes with IGSF9B expression in pan-
creatic tissue (p = 3.6 × 10− 6) from 171 individuals and
thyroid tissue (p = 5.6 × 10− 11) from 323 individuals
from the GTEx study [16]. The minor allele for this
polymorphism, which was more represented in pa-
tients with benign disease course, was associated with
lower IGSF9B expression (Additional file 1: Figure
S2). Of note, IGSF9B was highly expressed in cerebel-
lar hemisphere, cerebellum and also in cortex, hypo-
thalamus, and spinal cord; however, no eQTLs were
described for these tissues most likely due to the
lower number of samples analyzed in brain tissue
(105 samples from cerebellar hemisphere and 125
from cerebellum).
IGSF9B, CPXM2, and NLRP9 are expressed in brain
chronic active lesions from MS patients
Based on the negative results observed for IGSF9B,
CPXM2, and NLRP9 expression in peripheral blood,
we wondered whether selected genes associated with
MS disease course could play more specific roles at
the CNS level by investigating their expression in
brain tissue from patients. Figure 3 depicts the results
of IGSF9B, CPXM2, and NLRP9 immunohistochemis-
tries in brain tissue sections from chronic active
lesions of MS patients. IGSF9B showed a diffuse
neutrophil staining in both the gray and the white
matter. The most intense IGSF9B staining was de-
tected in the cytoplasm of microglia/macrophages and
astrocytes located at the margins of MS lesions,
where inflammatory activity is highest. IGSF9B immu-
nostaining was also observed in less active areas of
the lesions, albeit to a lesser degree compared to
more active areas. CPXM2 and NLRP9 exhibited a
similar and very discrete immunostaining. Their ex-
pression was restricted to the cytoplasm of few
microglia/macrophages located at the margins of MS
lesions showing the highest inflammatory activity
(Fig. 3).
Table 1 Description and functional consequences of SNPs selected for validation from exome sequencing
SNP Location (hg19) Gene Official full name Variant effect
rs17844444 (G/A) chr5:140,532,165 PCDHB6 Protocadherin Beta 6 Missense variant
rs17082236 (C/A) chr6:152,470,752 SYNE1 Spectrin repeat containing nuclear envelope protein 1 Missense variant
rs10279499 (C/A) chr7:92,733,766 SAMD9 Sterile alpha motif domain containing 9 Missense varianta
rs10488532 (C/T) chr7:92,764,489 SAMD9L Sterile alpha motif domain containing 9 like Missense variant
rs2374639 (T/C) chr7:92,985,252 VPS50 VPS50, EARP/GARPII complex subunit Synonymous variant
rs17552167 (C/T) chr7:148,529,922 EZH2 Enhancer of zeste 2 polycomb repressive complex 2 subunit Intronic variant
rs28469012 (A/T) chr10:125,622,263 CPXM2 Carboxypeptidase X, M14 family, member 2 Intronic variant
rs10894768 (C/G) chr11:133,815,981 IGSF9B Immunoglobulin superfamily member 9B Synonymous variant
rs60252902 (G/A) chr12:125,451,767 DHX37 DEAH-box helicase 37 Splice region variantb
rs3742130 (G/A) chr13:99,907,341 GPR18 G protein-coupled receptor 18 Synonymous variant
rs9919887 (A/G) chr14:95,911,008 SYNE3 Spectrin repeat containing nuclear envelope family member 3 Intronic variant
rs2230434 (C/T) chr16:30,518,096 ITGAL Integrin subunit alpha L Synonymous variant
rs2070896 (T/C) chr16:31,384,554 ITGAX Integrin subunit alpha X Intronic variant
rs35299026 (G/A) chr19:49,318,380 HSD17B14 Hydroxysteroid 17-beta dehydrogenase 14 Missense varianta
rs10423927 (A/G) chr19: 56,235,537 NLRP9 NLR family pyrin domain containing 9 Intronic variant
rs2254562 (T/C) chr21:34,059,352 SYNJ1 Synaptojanin 1 Missense varianta
aVariants reported as possible deleterious mutations (based on SIFT and PolyPhen-2 algorithms)
bBy definition, a splice region variant is a sequence variant in which a change has occurred within the region of the splice site, either within 1–3 bases of the
exon or 3–8 bases of the intron [30]
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Discussion
Exome sequencing has significantly contributed to the
characterization of the genetic component of a num-
ber of common complex diseases [19]. In the present
study, we aimed to identify genetic variants associated
with MS disease course by applying, as a first step,
an exome sequencing approach to a small discovery
cohort of patients stratified according to benign and
aggressive phenotypes. This initial approach led to the
identification of a ranked list of candidate polymor-
phisms associated either with benign or aggressive
MS disease courses. Despite the statistically significant
associations of a large number of SNPs with MS dis-
ease course, in small discovery cohorts only strong
statistically significant associations are likely to be
real, and hence original findings should be better rep-
licated in additional cohorts to eliminate the chances
of false positive results. Based on these observations,
in our study selected SNPs identified in the discovery
cohort were further genotyped in two independent
validation cohorts of patients classified according to
similar criteria into benign and aggressive phenotypes.
Meta-analysis in the two validation cohorts revealed
two polymorphisms, rs28469012 and rs10894768, as
potential MS phenotype modifiers. The SNP
rs28469012 is an intronic variant located in the CPXM2
gene whose minor allele was associated with worse dis-
ease evolution. CPXM2 codes for a member of the
metallocarboxypeptidase family with potential roles in
synaptic integrity [20]. Previous studies have associated
the CPXM2 gene to Alzheimer disease [21], Parkinson’s
disease [20], and schizophrenia [22]. Although no stud-
ies of CPXM2 have been reported thus far in MS, it is
interesting to mention that experimental autoimmune
encephalomyelitis (EAE) mice deficient for another
metallocarboxypeptidase that shares protein homology
with CPXM2, carboxipeptidase N, had attenuated EAE
disease course and reduced spinal cord inflammation
and demyelination [23], data that indirectly support the
association observed in our study between CPXM2 and
aggressive MS phenotypes.
The synonymous exonic variant rs10894768 is po-
sitioned in the IGSF9B gene, and the minor allele
for this polymorphism was more represented in MS
Table 2 Summary of statistical analysis of selected SNPs in the discovery and validation cohorts
Selected variants Discovery cohort (n = 20) First validation cohort
(n = 194)
Second validation cohort
(n = 257)
Meta-analysis
SNP Gene Minor allele MAF,
Benign
(n = 10)
MAF,
Aggressive
(n = 10)
p value MAF,
Benign
(n = 107)
MAF,
Aggressive
(n = 87)
MAF,
Benign
(n = 224)
MAF,
Aggressive
(n = 33)
Joint
p value
OR
(95% CI)
rs17844444 PCDHB6 A 0.10 0.40 0.03 0.15 0.15 0.18 0.14 0.52
rs17082236 SYNE1 A 0.00 0.35 0.003 0.09 0.1 0.05 0.07 0.54
rs10279499 SAMD9 A 0.45 0.00 0.0006 0.12 0.12 0.10 0.04 0.29
rs10488532 SAMD9L T 0.45 0.00 0.0006 0.12 0.14 0.12 0.06 0.79
rs2374639 VPS50 C 0.60 0.06 0.003 0.27 0.31 0.27 0.15 (*)
rs17552167 EZH2 T 0.30 0.00 0.007 0.07 0.06 0.08 0.12 0.63
rs28469012 CPXM2 T 0.05 0.45 0.003 0.04 0.10 0.10 0.12 0.04 1.81 [1.03–3.18]
rs10894768 IGSF9B G 0.50 0.05 0.001 0.35 0.28 0.36 0.27 0.04 0.70 [0.49–0.99]
rs60252902 DHX37 A 0.30 0.00 0.007 0.11 0.11 0.09 0.07 0.76
rs3742130 GPR18 A 0.55 0.05 0.0005 0.26 0.27 0.23 0.19 0.80
rs9919887 SYNE3 G 0.05 0.45 0.003 0.20 0.16 0.20 0.19 0.43
rs2230434 ITGAL T 0.00 0.25 0.01 0.11 0.09 0.09 0.07 0.32
rs2070896 ITGAX C 0.56 0.05 0.0006 0.37 0.38 0.33 0.32 0.85
rs35299026 HSD17B14 A 0.25 0.00 0.01 0.05 0.07 0.05 0.06 0.31
rs10423927 NLRP9 G 0.25 0.00 0.01 0.11 0.06 0.08 0.06 0.09 0.58 [0.31–1.09]
rs2254562 SYNJ1 C 0.05 0.45 0.003 0.30 0.29 0.29 0.35 0.65
The minor allele frequencies (MAF) and uncorrected p values for each SNP selected from the discovery cohort are presented. For validation, heterogeneity tests
and subsequent meta-analysis was performed in the two replication cohorts whenever possible. MAF and joint p values (calculated with Mantel-Haenszel test) are
depicted for each SNP. In addition, odds ratio (OR) with their corresponding 95% confidence intervals (95% CI) are presented for SNPs with statistically significant
results. *For SNP rs2374639, validation cohorts cannot be meta-analyzed due to high heterogeneity (I2 = 80%, p = 0.03). On a separate analysis, the first validation
cohort shows replication of the effect observed in the discovery cohort, with a lower frequency of the minor allele in aggressive MS compared to benign MS
[p = 0.04, OR = 0.47 (0.23–0.95)]. The second validation cohort shows an increased frequency of the minor allele in aggressive MS that is not statistically significant
[p = 0.39, OR = 1.22 (0.77–1.94)]
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patients with benign disease course. IGSF9B encodes
a transmembrane immunoglobulin that has been re-
ported to be highly expressed in GABAergic inter-
neurons, where it may play a role promoting
inhibitory synaptic development via the formation of
a ternary complex with the postsynaptic scaffolding
protein S-SCAM and the neuronal cell surface pro-
tein neuroligin 2 [24]. Similar to CPXM2, the role of
IGSF9B in MS is unknown. However, considering
that the GABAergic system is dysregulated in both
MS and EAE and a selective loss of GABAergic
interneurons has been reported in EAE [25], it is
tempting to speculate that the finding of a higher
frequency of genetic variants located in a gene that
promotes maintenance of inhibitory synapses may
result in more benign disease outcomes of MS pa-
tients. Noteworthy, MS brain tissue immunohisto-
chemistry revealed IGSF9B expression in astrocytes,
cells that are known to be involved in the formation
and control of neuronal synapses [26].
Although rs28469012 and rs10894768 were the only
polymorphisms whose association with MS disease
course was validated, a trend for association with be-
nign phenotypes was also observed for rs10423927, an
Fig. 2 Meta-analysis for rs28469012 (CPXM2), rs10894768 (IGSF9B), and rs10423927 (NLRP9) in the two validation cohorts of patients with
aggressive and benign disease courses. The figure depicts joint analyses for the first and second validation cohorts in each SNP, with
homogeneity tests (I2) and tests for overall effects. The squares and horizontal lines correspond to the study specific odds ratios (ORs) and 95%
confidence intervals (CI) respectively. The area of the squares reflects the study specific weight (inverse of the variance). The diamond represents
the pooled ORs and 95% CI. M-H Mantel-Haenszel
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intronic variant located in the NLRP9 gene. Despite
that little evidence exists in the literature regarding
its function, NLRP9 belongs to the NOD-like receptor
(NLR) family of inflammasomes, which are known to play
critical roles both in innate and adaptive immunity and
whose dysfunction has strongly been linked to auto-
immune diseases [27]. Interestingly, a missense variant lo-
cated in another member of the NLR family of
inflammasomes, NLRP5, was recently found to be associ-
ated with higher disease severity scores, suggesting a role
of NLR inflammasomes in MS disease course [28].
In an attempt to investigate the functional conse-
quences of the genetic variants associated with benign
and aggressive phenotypes, expression of IGSF9B,
CPXM2, and NLRP9 was investigated at the gene and
protein expression levels in PBMC and brain tissue
respectively. Although not proven in the study, the
negative results obtained in peripheral blood, with lack
of expression of CPXM2 and NLRP9 in PBMC and no
evidence of differences in IGSF9B expression between
minor allele carriers and non-carriers for rs10894768,
suggest that the genetic variants associated with disease
course in MS may act by modulating the function of
CNS cells such as macrophages/microglia and astrocytes,
as supported by the immunohistochemistry studies in MS
brain tissue showing expression for these genes in these
particular cell types. Unfortunately, postmortem brain
studies are not suitable for patient stratification to explore
allele-specific gene expression differences. Furthermore, it
could be possible that the MS course-associated allele of
our reported SNPs confers increased ability to interact
with certain environmental risk factors or impacts on
chromatin structure by affecting epigenetic marks, includ-
ing DNA methylation or histone modifications [29].
Finally, the finding that the minor allele of
rs10894768, which is more represented in MS patients
with benign outcomes, was associated with lower ex-
pression of IGSF9B in thyroid and pancreatic tissues
supports the view that gene expression may be markedly
different across tissues.
Fig. 3 IGSF9B, CPXM2, and NLRP9 expression in MS brain tissue. Immunostainings for IGSF9B, CPXM2, and NLRP9 in the margins of MS brain
chronic active lesions, where inflammatory activity is highest. IGSF9B expression was observed in astrocytes (arrows) and macrophages/microglia
(arrow heads), whereas CPMX2 and NLRP9 immunostaining was only detected in macrophages/microglia (arrow heads). Photos were taken at ×
20 and × 40
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Conclusions
In summary, we identified genetic variants in the IGSF9B,
CPXM2, and NLRP9 genes associated with benign and ag-
gressive disease phenotypes in MS patients. Interestingly,
the two genes that were validated in two independent
cohorts of MS patients, IGSF9B and CPXM2, are known to
play roles in CNS synapse integrity, findings that warrant
additional studies to explore at the CNS level the potential
functional consequences of the reported polymorphisms as-
sociated with MS disease course. Finally, aiming to provide
a personalized medicine in MS, the reported polymor-
phisms may become disease activity biomarkers to identify
MS patients with diverging disease courses.
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